Vitiligo
☆ AI Dermatology — Free Service
In die 2022 Stiftung Warentest-resultate van Duitsland was verbruikerstevredenheid met ModelDerm net effens laer as met betaalde telemedisyne-konsultasies.
In die 2022 Stiftung Warentest-resultate van Duitsland was verbruikerstevredenheid met ModelDerm net effens laer as met betaalde telemedisyne-konsultasies.
Vitiligo van die vingers is moeiliker om te behandel as ander areas. Behalwe dat dit kosmeties onooglik is, is vitiligo normaal en nie aansteeklik nie. In dermatologie is die mees effektiewe behandeling fototerapie of laserbehandeling (excimer), 2–3 keer per week, vir ten minste een jaar. As jy weens finansiële redes nie gereeld hospitaal kan besoek nie, of as jy besig is, kan jy ’n fototerapiemasjien probeer wat vir tuisgebruik goedgekeur is.
Vitiligo van die ooglid
Vitiligo by die hand
relevance score : -100.0%
ReferencesVitiligo is 'n algemene velafwyking wat kolle wit vel veroorsaak as gevolg van die verlies van melanosiete. Onlangse navorsing toon dat dit 'n outo‑immuun siekte is. Alhoewel dit dikwels as 'n kosmetiese probleem beskou word, kan dit die geestelike welstand en daaglikse lewe diep beïnvloed. In 2011 het kenners 'n tipe, genaamd segmental vitiligo, apart van ander geklassifiseer.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Actiewe vitiligo-pasiënte het verskeie terapie‑opsies, soos sistemiese glukokortikoïede, fototerapie en sistemiese immuunonderdrukkers. Stabiele vitiligo-pasiënte kan verligting vind met huidige kortikosteroïede, huidige kalsineurien‑inhibeerders, fototerapie en oorplantingsprosedures. Onlangse vooruitgang in die begrip van die onderliggende prosesse van vitiligo het gelei tot die ontwikkeling van geteikende terapieë. Tans is JAK-inhibeerders die mees belowende, aangesien hulle goeie verdraagsaamheid en funksionele uitkomste bied, ten spyte van die risiko van aktivering van latente infeksies en sistemiese newe‑effekte wat algemeen met ander immuunonderdrukkende middels voorkom. Deurlopende navorsing het ten doel om sleutelsitokiene wat betrokke is by die ontwikkeling van vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) te identifiseer. Die blokkering van hierdie sitokiene het belofte getoon in dieremodelle en by sommige pasiënte. Daarbenewens is navorsing na miRNA-based therapeutics en adoptive Treg cell therapy aan die gang.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Daar is geen bekende geneesmiddel vir vitiligo nie. Vir diegene met ligte vel is sonskerm en grimering die tipiese aanbevelings. Ander behandelingsopsies kan steroïedroom of fototerapie insluit.
○ Behandeling
#Phototherapy
#Excimer laser
#Tacrolimus ointment